Research findings can be used in antiviral development against enterovirus infections

Despite their prevalence, there are no antivirals on the market against enteroviruses, and vaccines have been developed only against couple of serotypes. The production of vaccines against all enterovirus serotypes is not feasible, and so antiviral drugs may be the solution for most of the enterovirus infections.

''For antiviral development, it is crucial to obtain detailed information about factors that contribute to efficient infection. In the future, these factors could then be the targets of antiviral development'', says Mira Laajala.

The information of Mira Laajala's research can potentially be used in the antiviral development against enterovirus infections. The research showed that in addition to viral proteases, cellular calpain proteases can cleave the enteroviral polyprotein.

This was shown in an in vitro study, but it gives a good starting point to study the phenomenon also in the cells during infection. In addition, a synthetic inhibitor against calpains was shown to prevent enterovirus infection in cells, which highlights the potential of calpain inhibitor as an antiviral against enteroviruses.''

Mira Laajala, researcher

New infectious intermediate particle was found in the research

Mira Laajala found also another cellular factor that contributed to enteroviruses infection. The study showed that cellular vimentin protein formed a cage-like structure around the replicating viral RNA and viral non-structural proteins during infection. In addition, it was revealed that the formation of vimentin cage was needed for efficient production of these viral non-structural proteins.

''This is an interesting finding since the non-structural proteins are the ones that are contributing to the pathogenesis of the virus'', says Mira Laajala.

In addition to the cellular factors, Laajala studied also the uncoating of the virus, so the step where viral RNA is released out from the capsid. The study revealed a new more open, but still infectious particle form. ''Uncoating intermediate particles have been described for enteroviruses before, but our new particle differed from those particles as it still contained all the capsid proteins and was able to bind on the receptor protein on the cell surface and cause infection'', says Laajala.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Stem cell therapy shows promise in treating COVID-19 complications